Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
Stephen K. Tahir(Abbott Fund), Darren C. Phillips(AbbVie (United States)), David Sharon(AbbVie (United States)), Mojca Jongen‐Lavrencic(Erasmus MC Cancer Institute), Susan E. Morgan-Lappe(Abbott Fund), Carla Biesdorf(AbbVie (United States)), Tamar Uziel(AbbVie (United States)), Morey L. Smith(AbbVie (United States)), Bruno C. Medeiros(Stanford Medicine), Emiliano Calvo(South Texas Accelerated Research Therapeutics), Kenichi Ishizawa(Yamagata University), Benedito A. Carneiro(Brown University), Eelke Gort(University Medical Center Utrecht), Aditya Shreenivas(City Of Hope National Medical Center), Junichiro Yuda(National Cancer Center Hospital East), Daniel Morillo(Sheba Medical Center), Monica Motwani(AbbVie (United States)), Dimple Modi(AbbVie (United States)), Fritz G. Buchanan(AbbVie (United States))
Cited by 30
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k